Targeting AMPK: A new therapeutic opportunity in breast cancer

Critical Reviews in Oncology/Hematology

Volumn 67, Issue 1, 2008, Pages 1-7

  Hadad, Sirwan M ^a   Fleming, Stewart ^a   Thompson, Alastair M ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

Akt; AMPK; Breast cancer; Cancer; Metformin; mTOR; Rapamycin; TSC

Indexed keywords

AP 23573; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; TEMSIROLIMUS;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER EPIDEMIOLOGY; CLINICAL TRIAL; DIABETES MELLITUS; HUMAN; IN VITRO STUDY; INCIDENCE; MEDLINE; NONHUMAN; REVIEW;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 44649104448     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.01.007     Document Type: Review

References (86)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
2. Besson A., Robbins S.M., and Yong V.W. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur J Biochem 263 (1999) 605-611
3. Sherr C.J. The pezcoller lecture: cancer cell cycles revisited. Cancer Res 60 (2000) 3689-3695
4. Guertin D.A., and Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 12 (2007) 9-22
5. Mita M.M., Mita A., and Rowinsky E.K. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 4 (2003) 126-137
6. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev 18 (2004) 1926-1945
7. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
8. Harris T.E., and Lawrence Jr. J.C. TOR signalling. Sci STKE 2003 (2003) re15
9. Jacinto E., and Hall M.N. Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 4 (2003) 117-126
10. Inoki K., and Guan K.L. Complexity of the TOR signaling network. Trends Cell Biol 16 (2006) 206-212
11. Vander Haar E., Lee S.I., Bandhakavi S., Griffin T.J., and Kim D.H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9 (2007) 316-323
12. Pearce L.R., Huang X., Boudeau J., et al. Identification of protor as a novel rictor-binding component of mTOR complex-2. Biochem J 405 (2007) 513-522
13. Inoki K., Corradetti M.N., and Guan K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37 (2005) 19-24
14. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by akt and suppresses mTOR signalling. Nat Cell Biol 4 (2002) 648-657
15. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., and Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10 (2002) 151-162
16. van Slegtenhorst M., Nellist M., Nagelkerken B., et al. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 7 (1998) 1053-1057
17. Feng Z., Zhang H., Levine A.J., and Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 102 (2005) 8204-8209
18. Schmelzle T., and Hall M.N. TOR, a central controller of cell growth. Cell 103 (2000) 253-262
19. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6 (2006) 729-734
20. Bose S., Chandran S., Mirocha J.M., and Bose N. The akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 19 (2006) 238-245
21. Sehgal S.N., Molnar-Kimber K., Ocain T.D., and Weichman B.M. Rapamycin: a novel immunosuppressive macrolide. Med Res Rev 14 (1994) 1-22
22. Sarbassov D.D., Ali S.M., and Sabatini D.M. Growing roles for the mTOR pathway. Curr Opin Cell Biol 17 (2005) 596-603
23. Sarbassov D.D., Ali S.M., Sengupta S., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22 (2006) 159-168
24. Kim J.E., and Chen J. Regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 53 (2004) 2748-2756
25. Dancey J.E. Clinical development of mammalian target of rapamycin inhibitors. Hematol Oncol Clin North Am 16 (2002) 1101-1114
26. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4 (2004) 335-348
27. Rowinsky E.K. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 16 (2004) 564-575
28. Vignot S., Faivre S., Aguirre D., and Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16 (2005) 525-537
29. Hudes G., Carducci M., Tomczak P., et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
30. Wan X., Harkavy B., Shen N., Grohar P., and Helman L.J. Rapamycin induces feedback activation of akt signaling through an IGF-1R-dependent mechanism. Oncogene 26 (2007) 1932-1940
31. O'Reilly K.E., Rojo F., She Q.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates akt. Cancer Res 66 (2006) 1500-1508
32. Sun S.Y., Rosenberg L.M., Wang X., et al. Activation of akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65 (2005) 7052-7058
33. Granville C.A., Memmott R.M., Gills J.J., and Dennis P.A. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 12 (2006) 679-689
34. Faivre S., Kroemer G., and Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5 (2006) 671-688
35. Hardie D.G., and Hawley S.A. AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays 23 (2001) 1112-1119
36. Hardie D.G., Scott J.W., Pan D.A., and Hudson E.R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 546 (2003) 113-120
37. Kemp B.E., Stapleton D., Campbell D.J., et al. AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 31 (2003) 162-168
38. Kahn B.B., Alquier T., Carling D., and Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1 (2005) 15-25
39. Alessi D.R., Sakamoto K., and Bayascas J.R. Lkb1-dependent signaling pathways. Annu Rev Biochem 75 (2006) 137-163
40. Bolster D.R., Crozier S.J., Kimball S.R., and Jefferson L.S. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 277 (2002) 23977-23980
41. Hardie D.G., and Carling D. The AMP-activated protein kinase-fuel gauge of the mammalian cell?. Eur J Biochem 246 (1997) 259-273
42. Winder W.W., and Hardie D.G. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol 270 (1996) E299-E304
43. Hutber C.A., Hardie D.G., and Winder W.W. Electrical stimulation inactivates muscle acetyl-CoA carboxylase and increases AMP-activated protein kinase. Am J Physiol 272 (1997) E262-E266
44. Hardie D.G., Carling D., and Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell?. Annu Rev Biochem 67 (1998) 821-855
45. Winder W.W., and Hardie D.G. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 277 (1999) E1-E10
46. Merrill G.F., Kurth E.J., Hardie D.G., and Winder W.W. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 273 (1997) E1107-E1112
47. Willer A. Reduction of the individual cancer risk by physical exercise. Onkologie 26 (2003) 283-289
48. Hu F.B., Manson J.E., Stampfer M.J., et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345 (2001) 790-797
49. Giardiello F.M., Brensinger J.D., Tersmette A.C., et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119 (2000) 1447-1453
50. Sanchez-Cespedes M., Parrella P., Esteller M., et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 62 (2002) 3659-3662
51. Ji H., Ramsey M.R., Hayes D.N., et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 448 (2007) 807-810
52. Hawley S.A., Boudeau J., Reid J.L., et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2 (2003) 28
53. Shaw R.J., Kosmatka M., Bardeesy N., et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101 (2004) 3329-3335
54. Woods A., Johnstone S.R., Dickerson K., et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13 (2003) 2004-2008
55. Lizcano J.M., Goransson O., Toth R., et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23 (2004) 833-843
56. Thomson D.M., Brown J.D., Fillmore N., et al. LKB1 and the regulation of malonyl-CoA and fatty acid oxidation in muscle. Am J Physiol Endocrinol Metab 293 (2007) E1572-E1579
57. Sakamoto K., McCarthy A., Smith D., et al. Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J 24 (2005) 1810-1820
58. Shaw R.J., Lamia K.A., Vasquez D., et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 (2005) 1642-1646
59. Sakamoto K., Goransson O., Hardie D.G., and Alessi D.R. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am J Physiol Endocrinol Metab 287 (2004) E310-E317
60. Towler M.C., and Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100 (2007) 328-341
61. 2+/calmodulin-dependent protein kinase kinase is involved in AMP-activated protein kinase activation by alpha-lipoic acid in C2C12 myotubes. Am J Physiol Cell Physiol 293 (2007) C1395-C1403
62. Hoyer-Hansen M., and Jaattela M. AMP-activated protein kinase: a universal regulator of autophagy?. Autophagy 3 (2007) 381-383
63. Cheng P.Y., Lee Y.M., Law K.K., Lin C.W., and Yen M.H. The involvement of AMP-activated protein kinases in the anti-inflammatory effect of nicotine in vivo and in vitro. Biochem Pharmacol 74 (2007) 1758-1765
64. Collins Q.F., Liu H.Y., Pi J., Liu Z., Quon M.J., and Cao W. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5′-AMP-activated protein kinase. J Biol Chem 282 (2007) 30143-30149
65. Evans J.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., and Morris A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ 330 (2005) 1304-1305
66. Bowker S.L., Majumdar S.R., Veugelers P., and Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: response to Farooki and Schneider. Diabetes Care 29 (2006) 1990-1991
67. Holland W., Morrison T., Chang Y., Wiernsperger N., and Stith B.J. Metformin (glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol 67 (2004) 2081-2091
68. Barker B., Fanger H., and Farnes P. Human mammary slices in organ culture. I: Method of culture and preliminary observations on the effect of insulin. Exp Cell Res 35 (1964) 437-448
69. van der Burg B., Rutteman G.R., Blankenstein M.A., de Laat S.W., and van Zoelen E.J. Mitogenic stimulation of human breast cancer cells in a growth factor-defined medium: synergistic action of insulin and estrogen. J Cell Physiol 134 (1988) 101-108
70. Gapstur S.M., Gann P.H., Colangelo L.A., et al. Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer Causes Control 12 (2001) 763-772
71. Kim Y.I. Diet, lifestyle, and colorectal cancer: is hyperinsulinemia the missing link?. Nutr Rev 56 (1998) 275-279
72. Del Giudice M.E., Fantus I.G., Ezzat S., McKeown-Eyssen G., Page D., and Goodwin P.J. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 47 (1998) 111-120
73. Giovannucci E. Insulin and colon cancer. Cancer Causes Control 6 (1995) 164-179
74. Yam D., Fink A., Mashiah A., and Ben-Hur E. Hyperinsulinemia in colon, stomach and breast cancer patients. Cancer Lett 104 (1996) 129-132
75. Zhou G., Myers R., Li Y., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108 (2001) 1167-1174
76. Zakikhani M., Dowling R., Fantus I.G., Sonenberg N., and Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66 (2006) 10269-10273
77. Hawley S.A., Gadalla A.E., Olsen G.S., and Hardie D.G. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51 (2002) 2420-2425
78. Kurose K., Zhou X.P., Araki T., Cannistra S.A., Maher E.R., and Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 158 (2001) 2097-2106
79. Kimura F., Watanabe J., Hata H., et al. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol 130 (2004) 161-168
80. Inoki K., Zhu T., and Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 (2003) 577-590
81. Shaw R.J., Bardeesy N., Manning B.D., et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6 (2004) 91-99
82. Kuhajda F.P., Pizer E.S., Li J.N., Mani N.S., Frehywot G.L., and Townsend C.A. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 97 (2000) 3450-3454
83. Menendez J.A., and Lupu R. Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Arch Immunol Ther Exp (Warsz) 52 (2004) 414-426
84. Xiang X., Saha A.K., Wen R., Ruderman N.B., and Luo Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 321 (2004) 161-167
85. Mazurek S., Michel A., and Eigenbrodt E. Effect of extracellular AMP on cell proliferation and metabolism of breast cancer cell lines with high and low glycolytic rates. J Biol Chem 272 (1997) 4941-4952
86. Motoshima H., Goldstein B.J., Igata M., and Araki E. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574 (2006) 63-71